Gennaro Sardella, Alessandro Spirito, Samantha Sartori, Dominick J Angiolillo, Pascal Vranckx, Jose M De la Torre Hernandez, Mitchell W Krucoff, Sripal Bangalore, Deepak L Bhatt, Gianluca Campo, Davide Cao, Bassem M Chehab, James W Choi, Yihan Feng, Junbo Ge, Katherine Godfrey, James Hermiller, Vijay Kunadian, Raj R Makkar, Aziz Maksoud, Franz-Josef Neumann, Hector Picon, Shigeru Saito, Holger Thiele, Ralph Toelg, Olivier Varenne, Birgit Vogel, Yujie Zhou, Marco Valgimigli, Stephan Windecker, Roxana Mehran
This analysis aimed to evaluate the effect of 1- versus 3-month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in older patients. Data from three prospective, single-arm studies (XIENCE Short DAPT Program), including high bleeding risk (HBR) patients successfully treated with an everolimus-eluting stent (XIENCE, Abbott) were analyzed. DAPT was discontinued at 1 or at 3 months in patients free from ischemic events and adherent to DAPT. Patients were stratified according to age (≥75 and <75 years)...
January 5, 2024: American Journal of Cardiology